David Aggen, Assistant Attending at Memorial Sloan Kettering Cancer Center, shared a post on X:
“A major challenge for patients on Enfortumab Vedotin for prolonged periods is mitigating neuropathy.
We are actively investigating the use of a novel MMAE binder to prevent neuropathy for patients with metastatic urothelial cancer.
ESMO trial in progress poster.”
You can also read: Phase Ib/II EV-103 at ESMO 2026: Long-Term Outcomes With Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Carcinoma
